Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan

Daiichi Sankyo Co Ltd DSNKY said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason.
However, the Nikkei newspaper reported that there were safety concerns.
In March, the company started a Phase 1 trial in Japan of an inhaled form of nafamostat mesylate with COVID-19 patients.
Nafamostat is used in the treatment of pancreatitis and has antiviral properties.
Price Action: DSNKY closed at $23.76 on Monday.